Bacil Pharma remains non-operational as annual profit masks losses
The company reported zero operating revenue for FY26, relying on other income to post a bottom-line profit.
— 9 earlier stories on Bacil Pharma Ltd. →What's new
- Bacil Pharma recorded zero revenue from operations for the full fiscal year.
- Total other income stood at ₹123.52 lakhs, resulting in a ₹155.55 lakhs profit after tax.
- Fair value adjustments caused a total loss of ₹61.88 lakhs.
Why this matters
The company exists as an entity without underlying commercial activity. While the auditor issued an unmodified opinion, the financial health depends on accounting items rather than actual business performance.
What we're watching
- Any sign of business revival or asset liquidation.
- Future auditor comments regarding the company's status.
- Persistence of fair value volatility in upcoming quarters.
The full read
Bacil Pharma stays locked in a non-operational state. The company ended the year with ₹0 in revenue from operations, relying entirely on ₹123.52 lakhs of other income to generate a reported profit after tax of ₹155.55 lakhs. Once fair value losses were accounted for, the bottom line shifted into a total loss of ₹61.88 lakhs. This is a routine annual disclosure. The auditor provided an unmodified opinion, a step up from previous disclaimers, but the core reality remains unchanged. The company holds no commercial momentum. It is a paper entity that produced no sales for the duration of the fiscal year. Nothing in these results breaks from the trends seen in quarterly updates.
Questions answered
- Does Bacil Pharma have any revenue?
- The company generated zero revenue from operations for FY26, though it reported ₹123.52 lakhs in other income.
- Did the company finish the year with a profit or a loss?
- It reported a profit after tax of ₹155.55 lakhs, but suffered a total loss of ₹61.88 lakhs after fair value adjustments.
Bacil Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on BACPHAR →- 22 May 2026 · 8:50 PM IST Bacil Pharma remains non-operational as annual profit masks losses
- today Bacil Pharma plans ₹50 cr rights issue — equal to its entire market cap
- 11d ago Mumbai investor Niraj Shah buys 6.44% stake in zero-revenue Bacil Pharma
- 15d ago Bacil Pharma loses another large holder as Shah sells 2.75% stake
- 16d ago Bacil Pharma loses another big holder — Patel cuts stake by 7.10%